Seres Therapeutics

Seres Therapeutics’ SER-155 Shows Promising Clinical Results
Tip Ranks
Thu, 09/12/24 - 07:26 pm
Seres Therapeutics
microbiome
clinical trials
SER-155
stem cell transplant
Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
BioPharma Dive
Thu, 06/6/24 - 11:46 am
Seres Therapeutics
microbiome
Nestle
C. difficile
FDA approves first oral microbiome therapy Vowst
Fierce Pharma
Thu, 04/27/23 - 11:53 am
Seres Therapeutics
microbiome
Vowst
SER-109
C. difficile
FDA
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Motley Fool
Tue, 04/4/23 - 11:25 pm
Arrowhead Pharmaceuticals
Seres Therapeutics
5 FDA decisions to watch in the second quarter
BioPharma Dive
Mon, 04/3/23 - 11:06 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biogen
tofersen
ALS
Seres Therapeutics
C. difficile
Pfizer
GSK
vaccines
RSV
Regeneron
Eylea
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Seres one step closer to bringing first oral microbiome therapy to market as FDA mulls approval
Fierce Biotech
Wed, 10/26/22 - 10:51 am
Seres Therapeutics
microbiome
C. difficile
SER-109
Plotting a comeback after 2016 flop, Seres to raise $100M to prep C. difficile program for launch
Endpoints
Thu, 06/30/22 - 11:04 am
Seres Therapeutics
microbiome
C. difficile
funding
Seres, Vera Notch Weekend Wins in C.Diff, Lupus Trials
BioSpace
Mon, 05/23/22 - 10:22 am
Seres Therapeutics
clinical trials
SER-109
C. difficile
Vera Therapeutics
lupus
atacicept
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
The year the regulators meet the microbiome
EP Vantage
Thu, 03/24/22 - 10:47 am
microbiome
Seres Therapeutics
Ferring Pharmaceuticals
FDA
C. difficile
Seres Therapeutics’ microbiome therapy flops against placebo as shares go into freefall
Fierce Biotech
Thu, 07/22/21 - 11:07 am
Seres Therapeutics
microbiome
ulcerative colitis
SER-287
clinical trials
8 key clinical trials to watch for the rest of 2021
BioPharma Dive
Mon, 06/21/21 - 11:11 am
clinical trials
Merck
Ridgeback Biotherapeutics
COVID-19
Intellia Therapeutics
transthyretin amyloidosis
Arcus Biosciences
Gilead Sciences
lung cancer
Sanofi
GSK
vaccines
uniQure
Huntington's disease
Mirati Therapeutics
gene editing
Seres Therapeutics
ulcerative colitis
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Finch Therapeutics Fetches $90M to Advance Microbiome Drug Pipeline
Xconomy
Thu, 09/17/20 - 10:42 am
microbiome
Finch Therapeutics
Seres Therapeutics
Battered and bruised Seres Therapeutics see shares skyrocket on phase 3 win
Fierce Biotech
Tue, 08/11/20 - 11:35 am
Seres Therapeutics
SER-109
C. difficile
microbiome
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
Marketwatch
Mon, 08/10/20 - 11:03 pm
Seres Therapeutics
microbiome
clinical trials
SER-109
Microbiome Report for Week Ending 6/22/19
CP Wire
Mon, 06/24/19 - 10:51 am
microbiome
Axial Biotherapeutics
EnteroBiotix
Seres Therapeutics
Synlogic
Ginkgo Bioworks
Microbiome Report for Week Ending 6/22/19
Mon, 06/24/19 - 09:41 am
microbiome
Axial Biotherapeutics
EnteroBiotix
Seres Therapeutics
Synlogic
Ginkgo Bioworks
Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering
CP Wire
Thu, 06/13/19 - 09:56 am
Seres Therapeutics
C. difficile
ulcerative colitis
Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering
Thu, 06/13/19 - 09:54 am
Seres Therapeutics
C. difficile
ulcerative colitis

Pages